Works matching Estrogen antagonists

Results: 1894
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer.

    Published in:
    NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00647-1
    By:
    • Grinshpun, Albert;
    • Russo, Douglas;
    • Ma, Wen;
    • Verma, Ana;
    • Hermida-Prado, Francisco;
    • Sherman, Shira;
    • Gaglia, Giorgio;
    • Kabraji, Sheheryar;
    • Kirkner, Gregory;
    • Hughes, Melissa E.;
    • Lin, Nancy U.;
    • Sandusky, Zachary;
    • Nardone, Agostina;
    • Guarducci, Cristina;
    • Nguyen, Quang-De;
    • Santagata, Sandro;
    • Nagy, Zsuzsanna;
    • Jeselsohn, Rinath
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30

    Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results.

    Published in:
    Breast Cancer Research, 2025, v. 27, n. 1, p. 1, doi. 10.1186/s13058-025-02049-y
    By:
    • Hamilton, Erika P.;
    • Patel, Manish R.;
    • Borges, Virginia F.;
    • Meisel, Jane L.;
    • Okera, Meena;
    • Alemany, Carlos A.;
    • Pluard, Timothy J.;
    • Wesolowski, Robert;
    • Sabanathan, Dhanusha;
    • Miller, Kathy D.;
    • Conlin, Alison K.;
    • McCarthy, Nicole;
    • Shaw, Morena;
    • Tonda, Margaret;
    • Shilkrut, Mark;
    • Lin, Nancy U.
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50